Omada Health Reports Strong Q3 2026 Results with Record Adjusted EBITDA and Raised Full-Year Guidance
Omada Health reported robust third-quarter 2026 financial results, highlighted by a 34% year-over-year revenue increase to $91.3 million. The company achieved record adjusted EBITDA of $12.4 million, marking a significant turnaround from the net loss reported in the same period last year. Growth was primarily driven by strong enrollment in diabetes and hypertension programs and an increasing shift toward higher-value multicondition sales. Operational efficiencies contributed to expanded margins, with GAAP gross margin rising to 76%. The company also demonstrated improved member retention and lower cost of revenue per member. Following these results, management raised its full-year 2026 guidance for both revenue and adjusted EBITDA, signaling confidence in continued momentum through the end of the year.
Tickers: $OMDA
Topics: EBITDA Gross Margin Membership Expansion Profitability Revenue Growth